Arlington Capital Partners Acquires Micron Technologies

WASHINGTON, DC – March 20, 2013 – Arlington Capital Partners (“Arlington”), a Washington, DC-based private equity firm, today announced the acquisition of Micron Technologies, Inc. (“Micron”), in partnership with the company’s management team. Headquartered in Malvern, PA, Micron is a leading global provider of particle size engineering and related analytical services to the pharmaceutical industry. Fairmount Partners, a Philadelphia based investment bank, represented Micron Technologies in the transaction

Micron focuses on solving the pharmaceutical industry’s most difficult bio-availability and drug delivery challenges through multiple particle size reduction technologies. The Company is the leading independent provider of micronization services for solubility enhancement of active pharmaceutical ingredients (“APIs”). Micron maintains state of the art facilities offering industry leading capabilities including distinctive containment technology for processing highly potent compounds.  Micron’s personnel have unique expertise in jet milling, mechanical milling, containment processing and associated analytical services including material characterization testing and stability monitoring.

“The combination of this top flight management team led by Joe Drost, with the experience of veteran pharmaceutical services investors at Arlington Capital, is certain to create a larger leader in contract manufacturing, and we expect great things from this excellent and balanced team.  Moreover, Arlington’s commitment to investing in growth matches up nicely with this management team’s track record of delivering it” remarked Neal McCarthy, Managing Director of Fairmount Partners.

“Micron’s ability to provide leading bio-availability solutions across the drug development spectrum, from clinical phases to the commercial market, positions the Company as a trusted long-term partner with its pharmaceutical clients for their most demanding drug development needs” said Matt Altman, a Partner at Arlington Capital Partners. “We are enthusiastic about building upon the Company’s leadership position and eager to continue to support the Company as it enhances and expands its global particle size engineering and analytical service offerings.”

Joseph Drost, CEO of Micron, commented, “We are extremely excited about our partnership with Arlington Capital. Arlington has a successful history of investing in healthcare and pharmaceutical services and shares our vision for growing Micron’s global capabilities and service offerings. Arlington’s ability to provide significant strategic and capital support will further enable Micron to continue to expand our leading global position and better serve our worldwide pharmaceutical client base.”

David Wodlinger, a Principal at Arlington Capital said, “Micron is an ideal platform investment in a compelling

growth industry and we look forward to working closely with the company’s management team to expand the business aggressively, both organically and through acquisition.”

Greenberg Traurig served as counsel to Arlington Capital Partners for the transaction. Fairmount Partners advised Micron on the transaction.

About Arlington Capital Partners

Arlington Capital Partners is a Washington, D.C.-based private equity firm with $1.5 billion of committed capital focused on middle market investment opportunities in growth industries including: healthcare services, aerospace/defense, government contracting, business services and software. The firm’s professionals and network have a unique combination of operating and private equity experience that enables Arlington to be a value-added investor. Arlington invests in companies in partnership with high quality management teams that are motivated to establish and/or advance their company’s position as

leading competitors in their field.

About Micron Technologies

Micron Technologies provides advanced solubility enhancement services including particle size reduction and analytical services for pharmaceutical companies worldwide.  Operating a new state-of-the-art 84,000 square foot cGMP facility in Malvern, PA and a 19,000 square foot cGMP facility in Dartford, U.K., Micron is uniquely positioned to serve the global needs of its clients from research and development to commercial scale volumes of APIs.  Micron’s highly skilled workforce of approximately 100 employees utilize advanced equipment and possess unique expertise to perform various processes including jet milling, mechanical milling, containment processing and associated analytical services including material characterization testing and stability monitoring.

About Fairmount Partners

Fairmount Partners is one of the largest investment banking groups in the Mid-Atlantic region. The firm specializes in advising middle-market growth companies with mergers and acquisitions, capital raising and strategic advice. Fairmount’s key focus areas include: IT and Business Services, Healthcare, Industrial/Consumer and Software/Technology. Fairmount has completed transactions throughout North and South America, Europe, Asia and Australia. For more information, visit:

Principals of Fairmount Partners acted as advisors to Micron in this transaction.

Neal McCarthy